Items Tagged ‘xtandi’

February 22nd, 2016

Xtandi® Improves Survival in Advanced Prostate Cancer

By

The agent Xtandi® (enzalutamide) improves survival and reduces the time to cancer progression compared to Casodex® (bicalutamide) among men with prostate cancer that has stopped responding to prior therapy with antiandrogens. These results were recently published as rapid communication in the Journal of Clinical Oncology. Prostate cancer is the most frequently diagnosed cancer in men […]

View full entry

Tags: bicalutamide, casodex, Early Stage I-II (A-B) Prostate Cancer, enzalutamide, Locally Advanced Stage III (C) Prostate Cancer, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, Refactory/Recurrent Prostate Cancer, xtandi


September 15th, 2014

FDA Approves Use of Xtandi for Chemotherapy Naïve Men With Advanced Prostate Cancer

By

The FDA approved the use of Xtandi® (enzalutamide) in men who have not yet received chemotherapy, significantly expanding the potential patient population eligible to be treated with the oral medicine.  Xtandi originally gained U.S. approval in 2012 for use in patients with castration-resistant prostate cancer that has spread beyond the prostate only after they had […]

View full entry

Tags: enazlutamide, hormone refractory, metastatic prostate cancer, Metastatic Stage IV (D) Prostate Cancer, News, PREVAIL trial, Prostate Cancer, Refactory/Recurrent Prostate Cancer, xtandi


June 18th, 2014

Combination Hormone Therapy Appears Safe and Effective in Reducing Testosterone in Metastatic Prostate Cancer

By

In a study presented at the 2014 American Society of Clinical Oncologists meeting, researchers reported that the use of two hormone blocking agents—Xtandi® (enzalutamide) and Zytiga® (abiraterone)—appeared safe and reduced testosterone levels in metastatic prostate cancer patients who had been resistant to initial hormone therapy. Cells in the prostate gland have testosterone receptors and when […]

View full entry

Tags: hormone therapy, Locally Advanced Stage III (C) Prostate Cancer, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, Refactory/Recurrent Prostate Cancer, xtandi, zytiga


June 16th, 2014

Xtandi Found to Delay Need for Chemotherapy in Metastatic Prostate Cancer Patients

By

In results of a phase III trial reported at the 2014 American Society of Clinical Oncologists, treatment with Xtandi® (enzalutamide) was found to significantly delay the need for chemotherapy in metastatic prostate cancer patients previously treated with hormone therapy. The trial, led by researchers at the Oregon Health and Sciences University, enrolled 1717 patients and […]

View full entry

Tags: metastatic prostate cancer, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, xtandi